HIV-VAC planning HIV/AIDS trials in Africa

HIV-VAC, Inc. announced to the press that it is working towards initiating human trials in one or more African countries where HIV/AIDS has reached epidemic proportions. These new trials in Africa would compliment trials currently underway in Russia, and will also be undertaken in conjunction with a major American University.

HIV-VAC's vaccine promises to provide a solution to this worldwide pandemic. Not only could it prevent the disease, and also may prevent the onset of AIDS in HIV - POSITIVE patients. HIV-VAC, Inc. is developing the Skinner HIV-VAC AIDS vaccine which is based on a new and very unique approach to neutralizing the AIDS virus. Unlike many other AIDS vaccines under development, the company believes that the Skinner vaccine has the potential to be effective with the AIDS virus' many mutant forms. This technology is based on a unique intracellular vaccine technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines. This has been under development by Dr Skinner and his team for the past 10 years at the University of Birmingham, UK.